Sanofi-Aventis U.S. has exercised its right to extend the term of its research collaboration with ImmunoGen, Inc. and will now provide research support funding through August 31, 2008. Also, effective September 1, 2006, ImmunoGen will no longer be obligated to present new targets for antibody-based anticancer therapeutics to Sanofi-Aventis, enabling the company to use such targets in the development of its own proprietary products. “We’re pleased that our relationship with Sano...